Full Text
PCN2 COST-EFFECTIVENESS OF IMATINIB (GLEEVEC)AS FIRST-LINE TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)

Abstract

Authors

K El Ouagari W Talbot JF Baladi

Back to Volume 7, Issue 6
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×